Levodopa-induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa-to-dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal glutamatergic transmission, and overstimulation of nicotinic acetylcholine receptors on dopamine-releasing axons. Delay in initiating levodopa is no longer recommended, as dyskinesia development is a function of disease duration rather than cumulative levodopa exposure. We review current and in-development treatments for peak-dose dyskinesia but suggest that improvements in levodopa delivery alone may reduce its future prevalence. Ann Neurol 2018;84:797–811.

Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., Lang, A. E., Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts, <<ANNALS OF NEUROLOGY>>, 2018; 84 (6): 797-811. [doi:10.1002/ana.25364] [http://hdl.handle.net/10807/170670]

Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts

Merola, Annamaria;Fasano, Alfonso;Calabresi, Paolo;
2018

Abstract

Levodopa-induced dyskinesia is a common complication in Parkinson disease. Pathogenic mechanisms include phasic stimulation of dopamine receptors, nonphysiological levodopa-to-dopamine conversion in serotonergic neurons, hyperactivity of corticostriatal glutamatergic transmission, and overstimulation of nicotinic acetylcholine receptors on dopamine-releasing axons. Delay in initiating levodopa is no longer recommended, as dyskinesia development is a function of disease duration rather than cumulative levodopa exposure. We review current and in-development treatments for peak-dose dyskinesia but suggest that improvements in levodopa delivery alone may reduce its future prevalence. Ann Neurol 2018;84:797–811.
2018
Inglese
Espay, A. J., Morgante, F., Merola, A., Fasano, A., Marsili, L., Fox, S. H., Bezard, E., Picconi, B., Calabresi, P., Lang, A. E., Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts, <<ANNALS OF NEUROLOGY>>, 2018; 84 (6): 797-811. [doi:10.1002/ana.25364] [http://hdl.handle.net/10807/170670]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/170670
Citazioni
  • ???jsp.display-item.citation.pmc??? 60
  • Scopus 215
  • ???jsp.display-item.citation.isi??? 197
social impact